Hello, myeloma world. How has your Friday been so far?

We have an eclectic mix of five new myeloma-related research studies that we'd like to discuss with you today.

Three of the studies involve laboratory (preclinical) research, which is the sort of research we often leave to discuss later in these reports. But all three of the laboratory studies we cover today address interesting topics, so we will be looking at them first.

The first laboratory study concerns

We tried, myeloma world, but we couldn't come up with a short title for today's report.

There were just too many words needed to describe the three research articles that we plan to review with you in this edition of Myeloma Morning.

First, we have an important new study out of Spain that in­ves­ti­gates the sig­nif­i­cance of Bence Jones protein in smol­der­ing multiple myeloma patients.

Next, we turn to a study by researchers in Japan. They in­ves­ti­gate different methods for measuring …

I have always watched my "numbers," such as blood counts and M-spike values, since having been diagnosed with multiple myeloma.

Here are some different kinds of numbers that come to mind when I reflect upon my seven-year journey:

10 SYLLABLES – When I started battling multiple myeloma in 2008, I felt like I was a David living in a Goliath’s world. My foe was a big, hairy beast of a cancer, and it was obvious that I couldn’t best him on …

A pleasant Tuesday to you, myeloma world.

We hope your week has started well. We been away for longer than ex­pec­ted, work­ing through some of the more technical details of the articles we discuss in today's Myeloma Morning.

Most of today's report focuses on two research articles that were published last week. Both articles were published in the journal Blood, and both are valuable contributions to what we know about multiple myeloma. As a result, we devote quite a bit …

A happy Saturday to you, myeloma world.

We hope your weekend has gotten off to an excellent start.

Today's edition of Myeloma Morning focuses primarily on a study that was included in yesterday's list of new myeloma-related research. The study summarizes trends in allogeneic (donor) stem cell transplantation in Europe over the last two decades.

Although the study focuses on European trends, we believe it should be of interest to Beacon readers regardless where they may be. With the global …

We're very glad to see you again, myeloma world.

Myeloma Morning was on brief hiatus while we helped with the Beacon's article about the recently published Ninlaro (ixazomib) clinical trial results.

Now that the Ninlaro article has been published, however, it's time to get back to normal Myeloma Morning business.

And there's a lot of it. In fact, there are almost 20 items in the list of new myeloma research at …

The results of an important Ninlaro (ixazomib) clin­i­cal trial have been published in a leading medical journal.

The "TOURMALINE-MM1" trial was instrumental in gaining Ninlaro ap­proval in the United States as a new treat­ment for multiple myeloma. The Phase 3 trial tested whether adding Ninlaro to Revlimid (lena­lido­mide) and dexa­metha­sone is safe and im­proves treat­ment out­comes in patients with re­lapsed multiple myeloma

Up until now, only limited results of the TOURMALINE-MM1 trial have been publicly avail­able. …